Craig B. Thompson
Known title: DirectorCIK: 0001423419
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock. Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.
Transaction History
| CRL | ▲ Buy | Grant | 1,438 | $255K | 5/8/2026 | View on chart |
| REGN | ▲ Buy | Grant | 155 | $0 | 1/2/2026 | View on chart |
| CRL | ▲ Buy | Grant | 946 | $128K | 5/21/2025 | View on chart |
| REGN | ▲ Buy | Grant | 166 | $0 | 1/2/2025 | View on chart |
| CRL | ▲ Buy | Grant | 559 | $128K | 5/13/2024 | View on chart |
| REGN | ▲ Buy | Grant | 135 | $0 | 1/2/2024 | View on chart |
| CRL | ▲ Buy | Grant | 664 | $0 | 5/15/2023 | View on chart |
| REGN | ▲ Buy | Grant | 40 | $0 | 1/3/2023 | View on chart |
| CRL | ▲ Buy | Grant | 244 | $0 | 1/3/2023 | View on chart |
| REGN | ▲ Buy | Grant | 279 | $0 | 10/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
CRL Analyst Targets Rise After UBS Reinstates Coverage
Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.
CRL Analyst Targets Rise After UBS Reinstates Coverage. Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.